Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Cantor Fitzgerald
Deloitte
Harvard Business School
US Department of Justice
UBS
Queensland Health
Accenture

Generated: December 16, 2018

DrugPatentWatch Database Preview

TYSABRI Drug Profile

« Back to Dashboard

Summary for Tradename: TYSABRI
Pharmacology for TYSABRI
Mechanism of ActionIntegrin Receptor Antagonists

US Patents for TYSABRI

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Children\'s Hospital Medical Center (Cincinnati, OH) Westfaelische Wilhelms-Universitaet Muenster (Muenster, DE) ➤ Sign Up RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Genentech, Inc. (South San Francisco, CA) ➤ Sign Up RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Sign Up RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Schutzer; Steven E. (New York, NY) ➤ Sign Up RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Momenta Pharmaceuticals, Inc. (Cambridge, MA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00238 Netherlands ➤ Sign Up PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
273 Luxembourg ➤ Sign Up 91273, EXPIRES: 20150831
0804237/01 Switzerland ➤ Sign Up FORMER OWNER: ELAN PHARMACEUTICALS, INC., US
C0024 France ➤ Sign Up PRODUCT NAME: NATALIZUMAB,ANTICORPS MONOCLONAL HUMANISE ANTI-INTEGRINE ALPHA-4; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
2006 00023 Denmark ➤ Sign Up PRODUCT NAME: NATALIZUMAB
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
US Army
US Department of Justice
Citi
Johnson and Johnson
Argus Health
Deloitte
Moodys
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.